![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS Number:2399E Cambridge Antibody Tech Group PLC 21 January 2000 For Further Information Contact: Cambridge Antibody Technology Group plc Dr David Chiswell, Chief Executive Officer John Aston, Finance Director Diane Mellett, Company Secretary, VP Legal Affairs Tel: +44 (0) 1763 263233 HCC.De Facto City/Financial, Sue Charles/Rebecca Hennessey Tel: +44 (0) 171 496 3300 RESULT OF EXTRAORDINARY GENERAL MEETING Melbourn, UK Cambridge Antibody Technology (CAT) announced that at the Extraordinary General Meeting held today the resolution to authorise the directors to issue shares to Monsanto Europe SA (MESA) in connection with the collaboration and subscription agreements entered into with GD Searle and MESA (its affiliate) on 23 December 1999 was passed. It is expected that the 1,870,837 new ordinary shares to be issued to MESA will be listed on Thursday 27 January 2000. Notes: Cambridge Antibody Technology (LSE: CAT) is a UK biotechnology company using its proprietary technologies in fully human monoclonal antibodies for drug discovery and drug development. Based in Melbourn, 10 miles south of Cambridge, England, CAT currently employs around 150 people. In March 1997, CAT completed its initial public offering and listing on the London Stock Exchange, raising approximately #41 million. CAT has a world-leading platform technology for rapidly isolating fully human monoclonal antibodies using phage display systems. CAT has an extensive phage display antibody library, currently incorporating around 100 billion distinct antibodies. This library forms the basis for the company's strategy to develop a portfolio of clinical development programmes and for discovering new drug leads using functional genomics. Four fully human therapeutic antibodies developed by CAT are at various stages of clinical trials. CAT has a number of license and collaborative agreements in place with pharmaceutical and biotechnology companies including: Eli Lilly, Pfizer, BASF Pharma, Genentech, ICOS Corporation, Genetics Institute/BASF Pharma, Wyeth-Ayerst, Human Genome Sciences, AstraZeneca and Searle. END RSEKKDKKOBKDBDB
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions